Patients
-
Webinars
-
Webinars
-
Webinars
COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patient Advocates from Europe
Patient Advocates from Greece, Germany, the UK, the Netherlands, Romania and other countries of the WHO European Region exchange thoughts and opinions with TIF about the daunting challenges and concerns…
Read More » -
Newsletter
-
TIF Publications
COVID-19 & Haemoglobin Disorders: A Classification of Risk Groups & Other Considerations (2020)
A document seeking to offer a risk level classification for thalassaemia and SCD patients in relation to the ongoing COVID-19 pandemic.
Read More » -
News
FDA Grants RMAT Designation to CTX-001™ for the Treatment of Severe TDT β-Thalassaemia & SCD
CRISPR Therapeutics and Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX-001, an investigational, autologous, Gene Editing hematopoietic stem cell therapy, for the treatment of severe Transfusion-Dependent β-Thalassaemia (TDT) and Sickle…
Read More » -
News
TIF’s Latest Guide for the COVID-19 Pandemic is Going Public on the International Thalassaemia Day 2020
As the online celebrations for the International Thalassaemia Day 2020 are at their peak, TIF decided to publish today as a gift to its worldwide patient communities a new guide entitled ”COVID-19…
Read More » -
News
Reblozyl (luspatercept-aamt) Receives Positive CHMP Opinion for the Treatment of Adults with β-Thalassaemia
On 30 April 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product REBLOZYL, intended for the treatment of adults…
Read More » -
TIF News
TIF’s Global Call for Solidarity & Cooperation in support of WHO
TIF expresses major concerns over the announcement of the United States to suspend financial support for the World Health Organisation (WHO) until completion of a review of the organisation’s activities related…
Read More » -
News
COVID-19: TIF Releases Position Statement on the Inclusion of Thalassaemia & SCD Patients in the High-Risk Population
The SARS-CoV-2 infection presents particular challenges and great risks to patients with thalassaemia and sickle cell disease (SCD) and, if their appropriate clinical management as described in International Guidelines is…
Read More »